C. Michael Gibson and Dean Kereiakes discuss the first human use of RUC-4, designed for STEMI point-of-care treatment. Receive the the latest news, research, and presentations from major meetings ...

This variability may reflect the heterogeneous nature of autoantibodies targeting GPIb/V/IX, GPIIb/IIIa and other platelet-related antigens. In addition to direct pathogenic effects of antibodies ...

The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated signaling, and glycoprotein IIb/IIIa-mediated platelet aggregation.

Despite being acaryote cell fragments, platelets share a number of properties of host defense with their big nucleated relatives and represent important elements in innate immunity. For these ...